London
· Delayed Price · Currency is GBP · Price in GBXHemogenyx Pharmaceuticals Statistics
Total Valuation
Hemogenyx Pharmaceuticals has a market cap or net worth of GBP 12.03 million. The enterprise value is 13.14 million.
| Market Cap | 12.03M |
| Enterprise Value | 13.14M |
Important Dates
The next estimated earnings date is Friday, December 27, 2024.
| Earnings Date | Dec 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Hemogenyx Pharmaceuticals has 3.50 million shares outstanding. The number of shares has increased by 20.74% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 3.50M |
| Shares Change (YoY) | +20.74% |
| Shares Change (QoQ) | +0.95% |
| Owned by Insiders (%) | 8.72% |
| Owned by Institutions (%) | 36.53% |
| Float | 3.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.76 |
| P/TBV Ratio | 4.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.53 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.62 |
Financial Position
The company has a current ratio of 4.38, with a Debt / Equity ratio of 0.92.
| Current Ratio | 4.38 |
| Quick Ratio | 4.38 |
| Debt / Equity | 0.92 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.55 |
| Interest Coverage | -13.64 |
Financial Efficiency
Return on equity (ROE) is -155.97% and return on invested capital (ROIC) is -39.69%.
| Return on Equity (ROE) | -155.97% |
| Return on Assets (ROA) | -37.79% |
| Return on Capital (ROIC) | -39.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -304,847 |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16,335.71% in the last 52 weeks. The beta is 3.15, so Hemogenyx Pharmaceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 3.15 |
| 52-Week Price Change | +16,335.71% |
| 50-Day Moving Average | 228.36 |
| 200-Day Moving Average | 58.18 |
| Relative Strength Index (RSI) | 49.83 |
| Average Volume (20 Days) | 4,386,259 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -4.03M |
| Pretax Income | -5.19M |
| Net Income | -5.18M |
| EBITDA | -3.80M |
| EBIT | -4.03M |
| Earnings Per Share (EPS) | -1.70 |
Balance Sheet
The company has 1.64 million in cash and 2.78 million in debt, giving a net cash position of -1.14 million or -0.33 per share.
| Cash & Cash Equivalents | 1.64M |
| Total Debt | 2.78M |
| Net Cash | -1.14M |
| Net Cash Per Share | -0.33 |
| Equity (Book Value) | 3.02M |
| Book Value Per Share | 0.91 |
| Working Capital | 1.91M |
Cash Flow
In the last 12 months, operating cash flow was -4.91 million and capital expenditures -104,124, giving a free cash flow of -5.02 million.
| Operating Cash Flow | -4.91M |
| Capital Expenditures | -104,124 |
| Free Cash Flow | -5.02M |
| FCF Per Share | -1.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Hemogenyx Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.74% |
| Shareholder Yield | -20.74% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
The last stock split was on December 13, 2024. It was a reverse split with a ratio of 0.0025.
| Last Split Date | Dec 13, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0025 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |